Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 183-185
DOI: 10.4103/sajc.sajc_211_18
ORIGINAL ARTICLE: Hematolymphoid Malignancies

Langerhans cell histiocytosis: An enigmatic disease

Anubha Jain
Department of Pediatrics, Division of Hematology‑Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Sushil Kumar
Department of Pediatrics, Division of Hematology‑Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Priyanka Aggarwal
Department of Pediatrics, Division of Hematology‑Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Mohan Kumar
Department of Pediatrics, Division of Hematology‑Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
,
Vineeta Gupta
Department of Pediatrics, Division of Hematology‑Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Langerhans cell histiocytosis (LCH) is a poorly understood disease with heterogeneous clinical presentation ranging from unifocal bony involvement to disseminated disease with life-threatening complications. Materials and Methods: The clinical profile, laboratory findings, treatment, and long-term outcome were retrieved from maintained medical records from January 2006 to January 2016 and were retrospectively analyzed. The extent of the disease was classified as per the LCH-III trial of “The Histiocyte Society.” The assessment and categorization of treatment response followed LCH III trial definitions. Results: A total of 28 children with LCH were diagnosed. The age ranged between 5 months and 9 years, with a mean of 3½ years. The M: F ratio was 3:1. Single system, unifocal and multifocal bone diseases were seen in nine (32.1%) and two (7.1%) cases, respectively. Disseminated disease without risk organ involvement was seen in six (21.1%), whereas disseminated disease with risk organ involvement was seen in 11 (39.3%) cases. The most common presentation was bony involvement (19 [67.8%]), out of which 16 (88.8%) had skull involvement. During follow-up, 17 (60.7%) were in complete remission though five (17.8%) of them relapsed, but achieved second remission. Two (7.1%) were lost to follow-up. Six (21.4%) had progressive disease of which four expired and two abandoned treatment. Two (10.7%) refused the initiation of treatment. Conclusion: A better understanding of the disease, early suspicion, and diagnosis can improve the outcome of patients with LCH.

Key words

Histiocytosis - Langerhans cell - outcome - risk organ - single system - survival


Publication History

Article published online:
21 December 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Histiocyte Society. Langerhans cell histiocytosis: Evaluation and Treatment Guidelines. Histiocyte Society; April, 2009.
  • 2 Bansal M, Srivastava VK, Bansal R, Gupta V, Bansal M, Patne S, et al. Severe periodontal disease manifested in chronic disseminated type of Langerhans cell histiocytosis in a 3-year old child. Int J Clin Pediatr Dent 2014;7:217-9.
  • 3 Gupta V, Bansal M. Cutaneous Langerhans cell histiocytosis. Indian Pediatr 2012;49:79.
  • 4 Bhat S, Nazir P, Bashir H, Reshi R, Sheikh S, Wani R, et al. Clinicopathological pattern of cranial unifocal Langerhans cell histiocytosis: A study at medical college hospital. Indian J Med Paediatr Oncol 2015;36:183-5.
  • 5 Bansal D, Marwaha RK, Trehan A, Gupta V, Varma N. Langerhans' cell histiocytosis: Experience from a single center. Indian Pediatr 2008;45:685-8.
  • 6 Singh T, Satheesh CT, Appaji L, Aruna Kumari BS, Mamatha HS, Giri GV, et al. Langerhan's cell histiocytosis: A single institutional experience. Indian J Med Paediatr Oncol 2010;31:51-3.
  • 7 Narula G, Bhagwat R, Arora B, Banavali S, Pai S, Nair C, et al. Clinico-biologic profile of Langerhans cell histiocytosis: A single institutional study. Indian J Cancer 2007;44:93-8.
  • 8 Uppal P, Bothra M, Seth R, Iyer V, Kabra SK. Clinical profile of Langerhans cell histiocytosis at a tertiary centre: A prospective study. Indian J Pediatr 2012;79:1463-7.
  • 9 Totadri S, Bansal D, Trehan A, Srinivasan R, Varma N, Kakkar N, et al. The 5-year EFS of multisystem LCH with risk-organ involvement is suboptimal: A single-center experience from India. J Pediatr Hematol Oncol 2016;38:e1-5.
  • 10 Kusuma Kumary P, Priyakumari T, Chellam VG, James FV, Nair MK. Langerhans cell histiocytosis in children less than 2 years of age. Indian Pediatr 1999;36:29-36.
  • 11 Dua V, Yadav SP, Sachdeva A. Treatment of relapsed/refractory Langerhans cell histiocytosis: A single centre experience. Indian J Pediatr 2014;81:315-6.
  • 12 Uppuluri R, Ramachandrakurup S, Subburaj D, Bakane A, Raj R. Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. Pediatr Blood Cancer 2017;64:110-2.